MVT 1075

Drug Profile

MVT 1075

Alternative Names: 177Lu Human Monoclonal Antibody 5B1; 177Lu- CHX-A″-DTPA-HuMAb-5B1; 177Lu-DTPA-HuMab-5B; 90Y- CHX-A″-DTPA-HuMAb-5B1; HuMab 5B1 radioimmunotherapy agent - MabVax; HuMab-5B1 conjugated Actinium225-radioimmunotherapy agent; MVT 1916; MVT-1075; radiolabeled HuMab 5B1 antibody - MabVax

Latest Information Update: 04 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MabVax Therapeutics
  • Developer MabVax Therapeutics; Memorial Sloan-Kettering Cancer Center
  • Class Antibodies; Antineoplastics; Immunoconjugates; Immunotherapies; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Colorectal cancer; Lung cancer; Pancreatic cancer

Most Recent Events

  • 27 Jun 2017 Phase-I clinical trials in Colorectal cancer (Combination therapy, Second-line therapy or greater, Metastatic disease, Late-stage disease) in USA (Parenteral)
  • 27 Jun 2017 Phase-I clinical trials in Lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral)
  • 01 Jun 2017 Phase-I clinical trials in Pancreatic cancer (Metastatic disease, Late-stage disease, Second-line therapy or greater, Combination therapy) in USA (Parenteral) (NCT03118349)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top